Core Insights - Nanox Imaging Ltd has announced a clinical and educational collaboration with Keiser University to deploy its advanced imaging system, Nanox.ARC, for training healthcare professionals [1][2] Company Overview - Nanox is focused on transforming healthcare through affordable medical imaging technologies, utilizing advanced AI and proprietary digital X-ray sources [6][7] - The company aims to enhance early detection and treatment of diseases, improving health outcomes globally [7] Product Details - The Nanox.ARC is a 3D digital tomosynthesis imaging system that offers improved sensitivity and specificity compared to traditional X-ray, while also reducing patient radiation exposure and radiologist reading times compared to CT scans [3][9] - The system features a proprietary digital X-ray source powered by cold cathode technology, providing a detailed, layered view of the body [3][9] Collaboration with Keiser University - The Nanox.ARC will be integrated into Keiser University's Radiologic Technology graduate program, allowing students and local medical imaging providers to access the technology for educational purposes [2][5] - This partnership is expected to enhance clinical education and empower future healthcare professionals with innovative diagnostic tools [5] Keiser University Overview - Keiser University is Florida's largest private, non-profit university, serving nearly 20,000 students across 21 campuses and online [4][10] - The university has awarded approximately 100,000 degrees since its establishment in 1977 and is recognized for its contributions to workforce talent in healthcare and nursing [4][10]

Nanox Analyst Day 2024 September 2024 Nanox Analyst Day 2024 2 Disclaimer Disclaimers This presentation has been prepared by NANO-X IMAGING LTD and its subsidiaries ("Nanox" or the "Company") and includes market data and other information from sources believed by the Company to be reliable. For example, industry and market data, including Nanox's own research, and surveys or industry publications and surveys as well as public information about Nanox's customers and discussion with them. Some data are also b ...

Nano-X Imaging (NNOX) Conference June 11, 2025 01:45 PM ET Speaker0 Welcome to submit questions using the Zoom Q and A interface at the bottom of your screen. After the presentation, we'll open to your questions. And with that, Ron, I'll turn it over to you. Speaker1 You, Alex, and good afternoon for everyone. Before we'll get started, I would like to remind everyone that I'll be making statements during this presentation that may be deemed forward looking statements regarding our activities, commercializat ...

Summary of Nano-X Imaging (NNOX) Conference Call Company Overview - **Company**: Nano-X Imaging Limited - **Industry**: Medical Imaging Technology - **Key Product**: Nanox ARC, a proprietary imaging device that combines advanced imaging technology with a cloud-based platform for enhanced medical diagnostics [4][6][13] Core Points and Arguments - **Technological Advancements**: The company is focused on improving medical imaging and patient outcomes through innovative technologies, including the Nanox ARC and AI solutions [4][21] - **Regulatory Approvals**: Achieved FDA clearance for musculoskeletal (MSK) imaging in May 2023 and CE marking for all body imaging in February 2025, indicating significant progress in regulatory compliance [21][23] - **Market Strategy**: Targeting the U.S. market with a focus on imaging centers, multi-specialty medical centers, and urgent care facilities. The company employs a direct sales team and partners with distributors for broader reach [23][24] - **Business Model**: Offers a pay-per-use model charging $30 per scan, requiring a minimum of seven scans per day under a multi-year agreement. This model is designed to minimize capital expenditure for operators [27][28] - **Financial Position**: As of March 31, 2025, the company reported $73 million in cash and cash equivalents, with a quarterly run rate of $3 million [50] Additional Important Content - **Product Features**: The Nanox ARC system is designed to be smaller, lighter, and simpler than traditional X-ray systems, providing 3D tomosynthesis images with reduced radiation exposure compared to CT scans [12][18] - **Clinical Benefits**: The technology allows for better visualization and reduced false positives, expediting diagnosis while maintaining lower costs compared to CT imaging [17][19] - **Future Developments**: The company is working on an upgraded version of the Nanox ARC with a smaller footprint and enhanced capabilities, which will allow for more installations in space-constrained environments [31][32] - **AI Solutions**: The company has developed AI solutions for various medical applications, including vertebral compression fractures and coronary artery calcium measurement, with plans for future applications in orthopedics and body composition [45][46] - **Global Presence**: The company has installations in the U.S., Israel, and Ghana, with ongoing clinical trials and partnerships to expand its market presence [30][49] Conclusion Nano-X Imaging Limited is positioned to disrupt the medical imaging industry with its innovative technology and business model, backed by regulatory approvals and a clear market strategy. The focus on cost-effective solutions and advanced imaging capabilities presents significant growth potential in the healthcare sector [4][21][23][27]

Core Viewpoint - Nanox Imaging Ltd has received EU MDR CE mark certification for its HealthOST software, enabling commercialization in Europe and ensuring compliance with regulatory standards for medical software [1][2]. Company Overview - Nanox is an innovative medical imaging technology company focused on preventive healthcare through affordable imaging technologies based on advanced AI [10][11]. - The company aims to enhance early detection and treatment of diseases, improving health outcomes globally [11]. Product Details - HealthOST is an advanced software solution that analyzes routine CT scans to assess vertebral height loss and bone mineral density, aiding in the evaluation of musculoskeletal diseases like osteoporosis [2][8]. - The software integrates with existing picture archiving and communication systems (PACS) and requires no additional imaging or patient time, making it a cost-effective screening tool [3][5]. Market Need - Osteoporosis affects over 25.5 million women in Europe, with a significant portion of vertebral compression fractures going undetected [4]. - The annual cost of osteoporosis-related fractures in Europe exceeds €56 billion, with cases expected to increase by 25% by 2034 due to an aging population [4]. Clinical Impact - In the ADOPT study, HealthVCF identified over 3,450 new patients with vertebral compression fractures, highlighting the software's effectiveness in detecting previously undiagnosed cases [6][7]. - The integration of Nanox.AI's solutions has shown to improve patient outcomes and reduce the burden on healthcare systems through preventive care [7].

Company Overview - Nanox Imaging Ltd (NASDAQ: NNOX) is an innovative medical imaging technology company focused on transitioning to preventive health care through affordable medical imaging technologies based on advanced AI and proprietary digital X-ray sources [3][4]. Upcoming Event - Nanox will participate in the Sidoti Small Cap Conference, scheduled for June 11-12, 2025, with management presenting on June 11 at 1:45 PM ET [1]. Technology and Solutions - The company aims to expand the reach of its technology beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, enhancing efficiency in routine medical imaging processes [4]. - Nanox's ecosystem includes several components: - Nanox.ARC, a cost-effective multi-source digital tomosynthesis system - Nanox.AI Ltd., which offers AI-based algorithms to augment routine CT imaging readings - Nanox.CLOUD, a cloud-based platform for data management and imaging analysis - Nanox.MARKETPLACE, a decentralized marketplace for remote access to radiology and cardiology experts [4]. Vision and Goals - The company's vision is to improve early detection and treatment of diseases, ultimately enhancing health outcomes worldwide [4].

Nano-X Imaging (NNOX) Q1 2025 Earnings Call May 22, 2025 08:30 AM ET Company Participants Mike Cavanaugh - Managing DirectorErez Meltzer - CEO & Acting Chairman of the BoardRan Daniel - Chief Financial OfficerJeffrey Cohen - MD - Equity Research Conference Call Participants Ross Osborn - Director, Lead Research Analyst - MedTech and DiagnosticsScott Henry - Managing Director & Senior Research Analyst Operator Good day, and thank you for standing by. Welcome to the Nano QX Q1 twenty twenty five Earnings Conf ...

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.2 million for Q1 2025, compared to a net loss of $12.2 million in Q1 2024, reflecting an increase of $1 million largely due to a $1.1 million increase in gross loss [27] - Revenue for Q1 2025 was $2.8 million, with a gross loss of $3 million, compared to revenue of $2.6 million and a gross loss of $2.1 million in the same period last year [27][28] - Non-GAAP gross loss for Q1 2025 was $400,000, down from a gross profit of $600,000 in Q1 2024, indicating a gross margin of approximately 15% for the reported period [28] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q1 2025 was $2.6 million, with a gross profit of $400,000, compared to $2.4 million and a gross profit of $300,000 in Q1 2024, representing a gross profit margin of approximately 17% [28] - Revenue from imaging systems and OEM services was $33,000 with a gross loss of $1.6 million in Q1 2025, compared to revenue of $47,000 and a gross loss of $400,000 in the same period last year [29] - Revenue from AI solutions was $200,000 with a gross loss of $1.9 million in Q1 2025, compared to $100,000 and a gross loss of $2 million in Q1 2024 [29] Market Data and Key Metrics Changes - The sales pipeline has doubled since January 2025, with the sales team handling over 1,000 leads, primarily from small and medium-sized health clinics in various countries [9] - The company is targeting over 100 ARC systems in various stages of deployment by the end of 2025, with over 60 units currently in various stages of implementation [10][11] Company Strategy and Development Direction - The company aims to improve medical imaging and enhance patient outcomes through strategic acquisitions and the integration of AI-powered imaging analysis [6][7] - The focus is on expanding the commercialization of Nanox ARC and AI solutions, with a multi-pronged strategy involving direct sales, collaborations, and distributor engagements [8][12] - The company is also pursuing opportunities in the workers' compensation segment, which presents a significant potential market [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged recent market uncertainties but expressed optimism about the growing base of early adopters for Nanox ARC [11] - The company expects its AI business to break even by 2026 and the ARC business to reach breakeven by 2027, with an anticipated inflection point in the second half of 2025 [57][58] Other Important Information - The company has received FDA clearance for the Nanox Arc X, enhancing its regulatory standing [20] - The company is actively engaged in clinical trials to generate data supporting the use of Nanox Arc, which is crucial for future growth [21] Q&A Session Summary Question: Can you provide details on the fleet deployment by the end of the year? - Management indicated that the majority of units will be in the US, with about 15-20% in Europe and 10% in other regions, depending on regulatory approvals [38] Question: What is the pricing and reimbursement status for the second opinion services? - The second opinion service is priced at approximately $300 and is primarily a retail model, with growing business potential [42] Question: How many units are currently deployed and operational in the US? - More than 20 units are currently installed, with some awaiting regulatory approvals [47] Question: What is the timeline for reaching breakeven across business lines? - The teleradiology division is already profitable, while the AI business is expected to break even in 2026 and the ARC business in 2027 [56][57]

Core Insights - Nanox Imaging Ltd reported a net loss of $13.2 million for Q1 2025, an increase from a net loss of $12.2 million in Q1 2024, primarily due to a $1.0 million increase in gross loss [3][8][13] - The company generated revenue of $2.8 million in Q1 2025, up from $2.6 million in Q1 2024, driven by teleradiology services, imaging systems sales, and AI solutions [4][8] - Nanox received FDA 510(k) clearance for its updated Nanox.ARC X system, marking a significant milestone in its mission to enhance access to medical imaging technology [2][8] Financial Performance - The gross loss for Q1 2025 was $3.0 million, with a gross loss margin of 108%, compared to a gross loss of $2.1 million and a margin of 80% in the prior year [5][8] - Non-GAAP gross loss for Q1 2025 was $0.4 million, a decline from a non-GAAP gross profit of $0.6 million in Q1 2024 [14][45] - Revenue from teleradiology services was $2.6 million in Q1 2025, up from $2.4 million in Q1 2024, with a GAAP gross profit margin of approximately 17% [6][8] Operational Highlights - The company has over 60 imaging units in various stages of implementation for commercial, demonstration, and clinical use [2] - Research and development expenses for Q1 2025 were $5.0 million, a slight decrease from $5.2 million in the prior year [10] - Sales and marketing expenses increased to $0.9 million in Q1 2025 from $0.8 million in Q1 2024 [11] Liquidity and Capital Resources - As of March 31, 2025, the company had total cash and cash equivalents of $72.9 million, down from $83.5 million at the end of 2024 [17] - The company experienced negative cash flow from operations of $10.3 million during the reported period [17][38] Future Outlook - Nanox anticipates that the number of clinical, demo, and commercial units will exceed 100 by the end of 2025, assuming stable macroeconomic conditions [16]

Core Insights - Nanox Imaging Ltd will report its financial results for Q1 2025 on May 22, 2025, before market open [1] - The conference call to discuss these results will be hosted by CEO Erez Meltzer and CFO Ran Daniel at 8:30 a.m. ET [1] Company Overview - Nanox is focused on transitioning to preventive healthcare through affordable medical imaging technologies utilizing advanced AI and proprietary digital X-ray sources [3] - The company's vision includes expanding its technology's reach beyond hospital settings, providing a comprehensive solution from scan to diagnosis, and leveraging AI for improved diagnostic accuracy [4] Product Ecosystem - Nanox.ARC is a multi-source digital tomosynthesis system designed to be cost-effective and user-friendly [4] - Nanox.AI LTD offers an AI-based suite of algorithms that enhance routine CT imaging readings to detect early signs of chronic diseases [4] - Nanox.CLOUD is a cloud-based platform for managing data from Nanox devices and providing tools for in-depth imaging analysis [4] - Nanox.MARKETPLACE is a decentralized marketplace providing remote access to radiology and cardiology experts, along with teleradiology services [4]